产品展示更多>>
- AVL-292 1202757-89-8
- AVL-292 1202757-89-8
AVL-292 1202757-89-8
产品描述 描述 AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed.
纯度 >98%储存/保存方法 Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.基本信息 别名 CC-292; AVL292; AVL-292; AVL 292;Spebrutinib外观 Powder可溶性/溶解性 DMSO 85 mg/mL (200.73 mM)生物活性 靶点 BTKIn vitro(体外研究) AVL-292 exhibits dose-dependent inhibition of Btk with EC50 of 8 nM and downstream BCR signaling components in Ramos cells. AVL-292, by inhibiting BTK activities, further inhibits B cell proliferation with EC50 of 3 nM.In vivo(体内研究) In a collagen-induced arthritis mouse model, AVL-292 (3- 30 mg/kg, p.o.) dose-dependently inhibits the clinical signs of inflammatory disease, including reduction in joint and paw swelling and visible redness of the affected paws.研究领域 研究领域 ImmunologyInnate ImmunityTLR SignalingSignal TransductionProtein PhosphorylationTyrosine KinasesOtherDrug DiscoverySmall Molecule DrugLead Compound DiscoveryAVL-292 1202757-89-8温馨提示：本产品仅作科研实验使用，不支持临床等研究